Evidence map›Paper›PMID 28873394›Full record

SynthesisPLoS neglected tropical diseases2017

Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform.

Jacob T Bush, Monique Wasunna, Fabiana Alves, Jorge Alvar, Piero L Olliaro, Michael Otieno, Carol Hopkins Sibley, Nathalie Strub Wourgaft, Philippe J Guerin

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. A systematic review and meta-analysis of patient data from the West Africa (2013-16) Ebola virus disease epidemic.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2019
    Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Strength in Numbers: The WWARN Case Study of Purpose-Driven Data Sharing.The American journal of tropical medicine and hygiene · 2019
    Article
  18. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.International journal for parasitology. Drugs and drug resistance · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jacob T BushCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.
Monique WasunnaDrugs for Neglected Diseases initiative, Nairobi, Kenya.
Fabiana AlvesDrugs for Neglected Diseases initiative, Geneva, Switzerland.
Jorge AlvarDrugs for Neglected Diseases initiative, Geneva, Switzerland.
Piero L OlliaroCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.
Michael OtienoCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.
Carol Hopkins SibleyCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.
Nathalie Strub WourgaftDrugs for Neglected Diseases initiative, Geneva, Switzerland.
Philippe J GuerinCentre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundThere are an estimated 200,000 to 400,000 cases of visceral leishmaniasis (VL) annually. A variety of factors are taken into account when considering the best therapeutic options to cure a patient and reduce the risk of resistance, including geographical area, malnourishment and HIV coinfection. Pooled analyses combine data from many studies to answer specific scientific questions that cannot be answered with individual studies alone. However, the heterogeneity of study design, data collection, and analysis often makes direct comparison difficult. Individual Participant Data (IPD) files can be standardised and analysed, allowing detailed analysis of this merged larger pool, but only a small fraction of systematic reviews and meta-analyses currently employ pooled analysis of IPD. We conducted a systematic literature review to identify published studies and studies reported in clinical trial registries to assess the feasibility of developing a VL data sharing platform to facilitate an IPD-based analysis of clinical trial data. Studies conducted between 1983 to 2015 that reported treatment outcome were eligible. PRINCIPAL

findingsFrom the 2,271 documents screened, 145 published VL clinical trials were identified, with data from 26,986 patients. Methodologies varied for diagnosis and treatment outcomes, but overall the volume of data potentially available on different drugs and dose regimens identified hundreds or possibly thousands of patients per arm suitable for IPD pooled meta-analyses.

conclusionsA VL data sharing platform would provide an opportunity to maximise scientific use of available data to enable assessment of treatment efficacy, contribute to evidence-based clinical management and guide optimal prospective data collection.

Indexed as

Age DistributionAntiprotozoal AgentsClinical Trials as TopicFemaleHumansInformation DisseminationLeishmaniasis, VisceralMaleTreatment OutcomeAntiprotozoal Agents

Identifiers

PMID28873394
PMCPMC5600407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.